These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 6869857

  • 41. In vivo and in vitro evaluation of the heparin management test versus the activated coagulation time for monitoring anticoagulation level in aprotinin-treated patients during cardiac surgery.
    Kim YS, Murkin JM, Adams SJ.
    Heart Surg Forum; 2004; 7(6):E599-604. PubMed ID: 15769695
    [Abstract] [Full Text] [Related]

  • 42. Activated partial thromboplastin time and activated coagulation time in monitoring heparinized cats.
    Greene CE, Meriwether E.
    Am J Vet Res; 1982 Aug; 43(8):1473-7. PubMed ID: 7103231
    [Abstract] [Full Text] [Related]

  • 43. Celite and kaolin produce differing activated clotting times during cardiopulmonary bypass under aprotinin therapy.
    Feindt P, Seyfert UT, Volkmer I, Straub U, Gams E.
    Thorac Cardiovasc Surg; 1994 Aug; 42(4):218-21. PubMed ID: 7529949
    [Abstract] [Full Text] [Related]

  • 44. Heparin detection by the activated coagulation time: a comparison of the sensitivity of coagulation tests and heparin assays.
    Murray DJ, Brosnahan WJ, Pennell B, Kapalanski D, Weiler JM, Olson J.
    J Cardiothorac Vasc Anesth; 1997 Feb; 11(1):24-8. PubMed ID: 9058215
    [Abstract] [Full Text] [Related]

  • 45. The effect of lysed platelets on neutralization of heparin in vitro with protamine as measured by the activated coagulation time (ACT).
    Bode AP, Castellani WJ, Hodges ED, Yelverton S.
    Thromb Haemost; 1991 Aug 01; 66(2):213-7. PubMed ID: 1771614
    [Abstract] [Full Text] [Related]

  • 46. Management of postoperative heparin rebound following cardiopulmonary bypass.
    Pifarré R, Babka R, Sullivan HJ, Montoya A, Bakhos M, El-Etr A.
    J Thorac Cardiovasc Surg; 1981 Mar 01; 81(3):378-81. PubMed ID: 7464201
    [Abstract] [Full Text] [Related]

  • 47. Heparin rebound phenomenon--much ado about nothing?
    Martin P, Horkay F, Gupta NK, Gebitekin C, Walker DR.
    Blood Coagul Fibrinolysis; 1992 Apr 01; 3(2):187-91. PubMed ID: 1606290
    [Abstract] [Full Text] [Related]

  • 48. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin.
    Francis JL, Howard C.
    Blood Coagul Fibrinolysis; 1993 Feb 01; 4(1):35-40. PubMed ID: 7681330
    [Abstract] [Full Text] [Related]

  • 49. [Perioperative management for hemicolectomy using propofol infusion in an elderly patient with a mechanical heart valve prosthesis].
    Tabuchi Y.
    Masui; 2000 Mar 01; 49(3):269-73. PubMed ID: 10752319
    [Abstract] [Full Text] [Related]

  • 50. Thrombin generation during cardiac surgery: is heparin the ideal anticoagulant?
    Brister SJ, Ofosu FA, Buchanan MR.
    Thromb Haemost; 1993 Aug 02; 70(2):259-62. PubMed ID: 8236131
    [Abstract] [Full Text] [Related]

  • 51. The monitoring of heparin administration by screening tests in experimental dogs.
    Mischke R, Jacobs C.
    Res Vet Sci; 2001 Apr 02; 70(2):101-8. PubMed ID: 11356088
    [Abstract] [Full Text] [Related]

  • 52. Measurement of activated coagulation time in children: evaluation of the blood-saving kaolin i-STAT activated coagulation time technique in pediatric cardiac anesthesia.
    Ulmer FF, Baulig W, Béttex D, Spielmann N, Bürki C, Weiss M.
    J Cardiothorac Vasc Anesth; 2011 Jun 02; 25(3):395-401. PubMed ID: 21376632
    [Abstract] [Full Text] [Related]

  • 53. [How much dosage of heparin do you administer? The relationship between heparin dosage and activated coagulation time (ACT) value during cardiovascular surgery: a multi center investigations].
    Shibasaki M, Nakajima Y, Kojima A, Kitagawa H, Tanimoto K, Mizobe T.
    Masui; 2010 Apr 02; 59(4):535-9. PubMed ID: 20420155
    [Abstract] [Full Text] [Related]

  • 54. Rapid quantitation of plasma heparin and antithrombin III levels for cardiopulmonary bypass monitoring, using fluorometric substrate assays.
    Savidge GF, Kesteven PJ, Al-Hasani SF, O'Brien PF.
    Thromb Haemost; 1983 Oct 31; 50(3):745-8. PubMed ID: 6648894
    [Abstract] [Full Text] [Related]

  • 55. Clotting, activated partial thromboplastin and coagulation times in monitoring heparin therapy.
    Kurec AS, Morris MW, Davey FR.
    Ann Clin Lab Sci; 1979 Oct 31; 9(6):494-500. PubMed ID: 518012
    [Abstract] [Full Text] [Related]

  • 56. Evaluation of heparin assay for coagulation management in newborns undergoing ECMO.
    Khaja WA, Bilen O, Lukner RB, Edwards R, Teruya J.
    Am J Clin Pathol; 2010 Dec 31; 134(6):950-4. PubMed ID: 21088159
    [Abstract] [Full Text] [Related]

  • 57. Platelet involvement in the activated coagulation time of heparinized blood.
    Moorehead MT, Westengard JC, Bull BS.
    Anesth Analg; 1984 Apr 31; 63(4):394-8. PubMed ID: 6367544
    [Abstract] [Full Text] [Related]

  • 58. Activated coagulation time test: a convenient monitor of heparinization for dogs used in cardiovascular research.
    Wilkerson RD, Conran PB, Greene SL.
    Lab Anim Sci; 1984 Feb 31; 34(1):62-5. PubMed ID: 6716959
    [Abstract] [Full Text] [Related]

  • 59. Effect of sodium heparin and antithrombin III concentration on activated partial thromboplastin time in the dog.
    Hellebrekers LJ, Slappendel RJ, van den Brom WE.
    Am J Vet Res; 1985 Jul 31; 46(7):1460-2. PubMed ID: 4026027
    [Abstract] [Full Text] [Related]

  • 60. In vitro effects of aprotinin on activated clotting time measured with different activators.
    Wang JS, Lin CY, Hung WT, Thisted RA, Karp RB.
    J Thorac Cardiovasc Surg; 1992 Oct 31; 104(4):1135-40. PubMed ID: 1383640
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 14.